{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T02:49:01Z","timestamp":1789181341570,"version":"build-2803163510"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Res."],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s44313-025-00102-5","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T12:50:20Z","timestamp":1760014220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Treatment of transplant-ineligible multiple myeloma"],"prefix":"10.1007","volume":"60","author":[{"given":"Jongheon","family":"Jung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"issue":"1","key":"102_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"102_CR2","doi-asserted-by":"publisher","first-page":"e263","DOI":"10.1093\/oncolo\/oyad053","volume":"28","author":"R Fonseca","year":"2023","unstructured":"Fonseca R, et al. Impact of treatment sequencing on overall survival in patients with transplant-ineligible newly diagnosed myeloma. Oncologist. 2023;28(5):e263\u20139.","journal-title":"Oncologist"},{"key":"102_CR3","doi-asserted-by":"crossref","unstructured":"Bharat Nandakumar MB, Angela Dispenzieri, Prashant Kapoor, Francis Buadi, Morie A, Gertz, Martha Lacy, David Dingli, Lisa Hwa, Nelson Leung, Suzanne R, Hayman, Wilson I, Gonsalves, Taxiarchis Kourelis, Eli Muchtar, Rahma M, Warsame, Ronald S, Go, Miriam A, Hobbs, Robert A, Kyle, S, Vincent Rajkumar, Shaji Kumar. Continued improvement in survival in multiple myeloma (MM) including high-risk patients. J Clin Oncol. 2019;37:8039\u20138039.","DOI":"10.1200\/JCO.2019.37.15_suppl.8039"},{"issue":"1","key":"102_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.jgo.2019.05.014","volume":"11","author":"H Mian","year":"2020","unstructured":"Mian H, et al. Autologous stem cell transplant in older patients (age >\/= 65) with newly diagnosed multiple myeloma: a systematic review and meta-analysis. J Geriatr Oncol. 2020;11(1):93\u20139.","journal-title":"J Geriatr Oncol"},{"issue":"1","key":"102_CR5","doi-asserted-by":"publisher","first-page":"51","DOI":"10.5045\/br.2021.2021176","volume":"57","author":"SI Kim","year":"2022","unstructured":"Kim SI, et al. Real-world evidence of levofloxacin prophylaxis in elderly patients with newly diagnosed multiple myeloma who received bortezomib, melphalan, and prednisone regimen. Blood Res. 2022;57(1):51\u20138.","journal-title":"Blood Res"},{"key":"102_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103504","volume":"168","author":"S Kiss","year":"2021","unstructured":"Kiss S, et al. Efficacy of first-line treatment options in transplant-ineligible multiple myeloma: a network meta-analysis. Crit Rev Oncol Hematol. 2021;168:103504.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"1","key":"102_CR7","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1111\/ejh.13530","volume":"106","author":"A Jones","year":"2021","unstructured":"Jones A, Bowcock S, Rachet B. Survival trends in elderly myeloma patients. Eur J Haematol. 2021;106(1):126\u201331.","journal-title":"Eur J Haematol"},{"issue":"9","key":"102_CR8","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1001\/jama.1969.03160090040009","volume":"208","author":"R Alexanian","year":"1969","unstructured":"Alexanian R. Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 1969;208(9):1680\u20135.","journal-title":"JAMA"},{"issue":"9513","key":"102_CR9","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S0140-6736(06)68338-4","volume":"367","author":"A Palumbo","year":"2006","unstructured":"Palumbo A, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367(9513):825\u201331.","journal-title":"Lancet"},{"issue":"8","key":"102_CR10","doi-asserted-by":"publisher","first-page":"3107","DOI":"10.1182\/blood-2008-04-149427","volume":"112","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, et al. Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. Blood. 2008;112(8):3107\u201314.","journal-title":"Blood"},{"issue":"9","key":"102_CR11","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906\u201317.","journal-title":"N Engl J Med"},{"issue":"1","key":"102_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s11596-018-1844-y","volume":"38","author":"SD Mu","year":"2018","unstructured":"Mu SD, et al. Subcutaneous versus intravenous bortezomib administration for multiple myeloma patients: a meta-analysis. Curr Med Sci. 2018;38(1):43\u201350.","journal-title":"Curr Med Sci"},{"issue":"23","key":"102_CR13","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","volume":"116","author":"S Bringhen","year":"2010","unstructured":"Bringhen S, et al. Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood. 2010;116(23):4745\u201353.","journal-title":"Blood"},{"issue":"7","key":"102_CR14","doi-asserted-by":"publisher","first-page":"1769","DOI":"10.1007\/s00277-021-04529-5","volume":"100","author":"MJ Cejalvo","year":"2021","unstructured":"Cejalvo MJ, et al. Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma. Ann Hematol. 2021;100(7):1769\u201378.","journal-title":"Ann Hematol"},{"issue":"10","key":"102_CR15","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa1402551","volume":"371","author":"L Benboubker","year":"2014","unstructured":"Benboubker L, et al. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med. 2014;371(10):906\u201317.","journal-title":"N Engl J Med"},{"issue":"3","key":"102_CR16","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1182\/blood-2017-07-795047","volume":"131","author":"T Facon","year":"2018","unstructured":"Facon T, et al. Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. Blood. 2018;131(3):301\u201310.","journal-title":"Blood"},{"key":"102_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2020.100757","volume":"46","author":"C Poh","year":"2021","unstructured":"Poh C, Keegan T, Rosenberg AS. Second primary malignancies in multiple myeloma: a review. Blood Rev. 2021;46:100757.","journal-title":"Blood Rev"},{"issue":"2","key":"102_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1093\/annonc\/mdw606","volume":"28","author":"P Musto","year":"2017","unstructured":"Musto P, et al. Second primary malignancies in multiple myeloma: an overview and IMWG consensus. Ann Oncol. 2017;28(2):228\u201345.","journal-title":"Ann Oncol"},{"issue":"1","key":"102_CR19","doi-asserted-by":"publisher","DOI":"10.1007\/s44313-024-00025-7","volume":"59","author":"CY Huh","year":"2024","unstructured":"Huh CY, et al. Comparative efficacy of VMP vs. Rd in newly diagnosed, autologous stem cell transplant-ineligible multiple myeloma patients: a prematurely terminated randomized controlled study, CAREMM-2002 study. Blood Res. 2024;59(1):24.","journal-title":"Blood Res"},{"issue":"10068","key":"102_CR20","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","volume":"389","author":"BGM Durie","year":"2017","unstructured":"Durie BGM, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial. Lancet. 2017;389(10068):519\u201327.","journal-title":"Lancet"},{"issue":"5","key":"102_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-0311-8","volume":"10","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). Blood Cancer J. 2020;10(5):53.","journal-title":"Blood Cancer J"},{"issue":"2","key":"102_CR22","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bjh.15261","volume":"182","author":"EK O'Donnell","year":"2018","unstructured":"O\u2019Donnell EK, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018;182(2):222\u201330.","journal-title":"Br J Haematol"},{"issue":"6","key":"102_CR23","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378(6):518\u201328.","journal-title":"N Engl J Med"},{"issue":"10218","key":"102_CR24","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/S0140-6736(19)32956-3","volume":"395","author":"MV Mateos","year":"2020","unstructured":"Mateos MV, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial. Lancet. 2020;395(10218):132\u201341.","journal-title":"Lancet"},{"key":"102_CR25","doi-asserted-by":"crossref","unstructured":"Fu W, et al. Daratumumab, bortezomib, melphalan, and prednisone versus bortezomib, melphalan, and prednisone alone in transplant-ineligible Asian patients with newly diagnosed multiple myeloma: final analysis of the phase 3 OCTANS Study. Ann Hematol. 2024.","DOI":"10.1007\/s00277-024-05958-8"},{"issue":"22","key":"102_CR26","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","volume":"380","author":"T Facon","year":"2019","unstructured":"Facon T, et al. Daratumumab plus lenalidomide and dexamethasone for untreated myeloma. N Engl J Med. 2019;380(22):2104\u201315.","journal-title":"N Engl J Med"},{"issue":"11","key":"102_CR27","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582\u201396.","journal-title":"Lancet Oncol"},{"issue":"12","key":"102_CR28","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/ajh.25963","volume":"95","author":"BGM Durie","year":"2020","unstructured":"Durie BGM, et al. Daratumumab-lenalidomide-dexamethasone vs standard-of-care regimens: efficacy in transplant-ineligible untreated myeloma. Am J Hematol. 2020;95(12):1486\u201394.","journal-title":"Am J Hematol"},{"issue":"1","key":"102_CR29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.clml.2023.09.003","volume":"24","author":"LN Gordan","year":"2024","unstructured":"Gordan LN, et al. Progression-free survival of Daratumumab versus Bortezomib triplet combination with Lenalidomide and Dexamethasone in transplant ineligible patients with newly diagnosed multiple myeloma: TAURUS chart review study. Clin Lymphoma Myeloma Leuk. 2024;24(1):55\u201363.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"102_CR30","doi-asserted-by":"publisher","unstructured":"Lytvynova O, et al. Insights from clinical trials: evidence-based recommendations for induction treatment of newly diagnosed transplant-eligible multiple myeloma. Antibodies (Basel). 2024. https:\/\/doi.org\/10.3390\/antib13040080.","DOI":"10.3390\/antib13040080"},{"issue":"17","key":"102_CR31","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, et al. Isatuximab, bortezomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2024;391(17):1597\u2013609.","journal-title":"N Engl J Med"},{"issue":"8","key":"102_CR32","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1038\/s41591-024-03050-2","volume":"30","author":"X Leleu","year":"2024","unstructured":"Leleu X, et al. Isatuximab, lenalidomide, dexamethasone and bortezomib in transplant-ineligible multiple myeloma: the randomized phase 3 BENEFIT trial. Nat Med. 2024;30(8):2235\u201341.","journal-title":"Nat Med"},{"key":"102_CR33","doi-asserted-by":"crossref","unstructured":"Usmani SZ, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med. 2025.","DOI":"10.1016\/S2152-2650(25)01288-1"},{"key":"102_CR34","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1182\/blood-2024-203170","volume":"144","author":"M-V Mateos","year":"2024","unstructured":"Mateos M-V, Paiva B, Cedena Romero MT, Puig N, Sureda Balari A, Oriol A, et al. GEM2017fit phase 3 trial in fit elderly patients (aged 65\u201380) with newly diagnosed myeloma: impact of daratumumab at induction and\/or consolidation. Blood. 2024;144:678.","journal-title":"Blood"},{"issue":"8","key":"102_CR35","first-page":"2594","volume":"109","author":"E Terpos","year":"2024","unstructured":"Terpos E, et al. Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I\/II study. Haematologica. 2024;109(8):2594\u2013605.","journal-title":"Haematologica"},{"key":"102_CR36","doi-asserted-by":"crossref","unstructured":"Ajay K, Nooka TC, Anita D'Souza, Jeffrey V Matous, Peter M, Voorhees, Karthik Ramasamy, Aurore Perrot, Andrew Spencer, Cyrille Hulin, Hang Quach, Deeksha Vishwamitra, Ashley Nguyen, Debopriya Ghosh, Elizabeth Shearin, Gary E Mason, Thomas Renaud, Gurdeep Parmar, Talquetamab, a GPRC5D\u00d7CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study. Blood, 2024;144:1975.","DOI":"10.1182\/blood-2024-199773"},{"key":"102_CR37","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.1182\/blood-2024-199913","volume":"144","author":"CD Wenqiang Yan","year":"2024","unstructured":"Wenqiang Yan CD. Rui Lv, Tengteng Yu, Shuaishuai Zhang, Tingyu Wang, Weiwei Sui, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou, Lu-Gui Qiu, Gang An, BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001). Blood. 2024;144:3385.","journal-title":"Blood"},{"issue":"13","key":"102_CR38","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","volume":"125","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, et al. Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. Blood. 2015;125(13):2068\u201374.","journal-title":"Blood"},{"issue":"1","key":"102_CR39","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41375-019-0539-0","volume":"34","author":"T Facon","year":"2020","unstructured":"Facon T, et al. A simplified frailty scale predicts outcomes in transplant-ineligible patients with newly diagnosed multiple myeloma treated in the FIRST (MM-020) trial. Leukemia. 2020;34(1):224\u201333.","journal-title":"Leukemia"},{"issue":"5","key":"102_CR40","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3324\/haematol.2016.162693","volume":"102","author":"M Engelhardt","year":"2017","unstructured":"Engelhardt M, et al. A concise revised myeloma comorbidity index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica. 2017;102(5):910\u201321.","journal-title":"Haematologica"},{"issue":"3","key":"102_CR41","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1016\/S2352-3026(18)30220-5","volume":"6","author":"G Cook","year":"2019","unstructured":"Cook G, et al. A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK myeloma research alliance risk profile): a development and validation study. Lancet Haematol. 2019;6(3):e154\u201366.","journal-title":"Lancet Haematol"},{"issue":"11","key":"102_CR42","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1002\/ajh.24532","volume":"91","author":"P Milani","year":"2016","unstructured":"Milani P, et al. N-terminal fragment of the type-B natriuretic peptide (NT-proBNP) contributes to a simple new frailty score in patients with newly diagnosed multiple myeloma. Am J Hematol. 2016;91(11):1129\u201334.","journal-title":"Am J Hematol"},{"issue":"1","key":"102_CR43","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41408-023-00843-5","volume":"13","author":"H Mian","year":"2023","unstructured":"Mian H, et al. Dynamic frailty risk assessment among older adults with multiple myeloma: a population-based cohort study. Blood Cancer J. 2023;13(1):76.","journal-title":"Blood Cancer J"},{"issue":"4","key":"102_CR44","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","volume":"36","author":"T Facon","year":"2022","unstructured":"Facon T, et al. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA. Leukemia. 2022;36(4):1066\u201377.","journal-title":"Leukemia"},{"issue":"25","key":"102_CR45","doi-asserted-by":"publisher","first-page":"2758","DOI":"10.1200\/JCO.20.03143","volume":"39","author":"CAM Stege","year":"2021","unstructured":"Stege CAM, et al. Ixazomib, daratumumab, and low-dose dexamethasone in frail patients with newly diagnosed multiple myeloma: the hovon 143 study. J Clin Oncol. 2021;39(25):2758\u201367.","journal-title":"J Clin Oncol"},{"key":"102_CR46","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1182\/blood-2024-203045","volume":"144","author":"JL Salomon Manier","year":"2024","unstructured":"Salomon Manier JL, Cyrille Hulin, Kamel Laribi, Carla Araujo, Gian Matteo Pica, Cyrille Touzeau, Pascal Godmer, Bohrane Slama, Lionel Karlin, Frederique Orsini Piocelle, Mamoun Dib, Magaret Macro, Laurence Sanhes, Lydia Montes, Abderrazak El Yamani, Mourad Tiab, Reza Tabrizi, Laurent Garderet, Bruno Royer, Benoit Bareau, Aurore Perrot, Jean Yves Mary, Jill Corre, Herve Avet Loiseau, Philippe Moreau, Xavier Leleu, Thierry Facon. The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma. Blood. 2024;144:774.","journal-title":"Blood"},{"issue":"2","key":"102_CR47","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1016\/S2352-3026(24)00347-8","volume":"12","author":"FB Askeland","year":"2025","unstructured":"Askeland FB, et al. Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2025;12(2):e120\u20137.","journal-title":"Lancet Haematol"}],"container-title":["Blood Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00102-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44313-025-00102-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44313-025-00102-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T14:03:45Z","timestamp":1760018625000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44313-025-00102-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["102"],"URL":"https:\/\/doi.org\/10.1007\/s44313-025-00102-5","relation":{},"ISSN":["2287-979X","2288-0011"],"issn-type":[{"value":"2287-979X","type":"print"},{"value":"2288-0011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"22 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This review article was conducted in accordance with the principles of the Declaration of Helsinki. Human ethics and consent to participate in the declarations were not applicable, and ethics approval was not required owing to the nature of this study as a review article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"53"}}